{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:35:44Z","timestamp":1788881744173,"version":"build-2803163510"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Elevated plasma homocysteine (Hcy) concentrations are associated with Alzheimer's disease and vascular dementia. Several recent reports have indicated that L-dopa treatment is an acquired cause of hyperhomo-cysteinemia. Despite the fact that a large proportion of Parkinson's disease (PD) patients develop cognitive dysfunctions or dementia, particularly in the late stages of the illness and after long-term L-dopa treatment, the relationship between Hcy and dementia in PD has not been fully investigated. The aim of this study was to evaluate plasma Hcy levels in a group of L-dopa-treated PD patients with cognitive impairment and to elucidate a possible role of Hcy in the development of cognitive dysfunctions in PD. We compared Hcy, vitamin B<\/jats:p>","DOI":"10.1515\/cclm.2005.193","type":"journal-article","created":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T13:09:11Z","timestamp":1128085751000},"source":"Crossref","is-referenced-by-count":29,"title":["Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions"],"prefix":"10.1515","volume":"43","author":[{"given":"Stefano","family":"Zoccolella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Iliceto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Diroma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Armenise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Defazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona V.","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fraddosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"de Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Livrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref51","first-page":"527","article-title":"Sulfate and cysteine levels in the plasma of patients with Parkinson s disease","volume":"16","author":"Allain","year":"1995","journal-title":"Neurotoxicology"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"405","DOI":"10.18388\/abp.2004_3580","article-title":"Methylation demand : a key determinant of homocysteine metabolism","volume":"51","author":"Brosnan","year":"2004","journal-title":"Acta Biochim Pol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.archger.2004.04.027","article-title":"De Homocysteine in Alzheimer disease and vascular dementia Arch Gerontol","volume":"9","author":"Gallucci","year":"2004","journal-title":"Geriatr Suppl"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","article-title":"Effects of homocysteine on the dopaminergic system and behaviour in rodents","volume":"26","author":"Lee","year":"2005","journal-title":"Neurotoxicology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","article-title":"Nigral endothelial dysfunction , homocysteine and Parkinson s disease","volume":"354","author":"Muller","year":"1999","journal-title":"Lancet"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","article-title":"Elevated plasma homocysteine levels in patients with Parkinson s disease Motor affective and cognitive associations","volume":"61","author":"Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1474-9728.2004.00086.x","article-title":"Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation","volume":"3","author":"Tijattas","year":"2004","journal-title":"Aging Cells"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.WNL.0000137886.74175.5A","article-title":"Homocysteine and levodopa : should Parkinson disease patients receive preventative therapy","volume":"63","author":"Postuma","year":"2004","journal-title":"Neurology"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0166-2236(03)00032-8","article-title":"Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders","volume":"26","author":"Mattson","year":"2003","journal-title":"Trends Neurosci"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","article-title":"Hypertrophy of IMC of carotid artery in Parkinson s disease is associated with levodopa , homocysteine and MTHFR genotype","volume":"207","author":"Nakaso","year":"2003","journal-title":"J Neurol Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1022130217463","article-title":"Hyperhomocysteinemia vascular function and atherosclerosis : effects of vitamins","volume":"16","author":"Haynes","year":"2002","journal-title":"Cardiovasc Drug Ther"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/WNL.55.3.437","article-title":"Plasma homocysteine and MTHFR genotype in levodopa treated patients with PD","volume":"55","author":"Yasui","year":"2000","journal-title":"Neurology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1212\/01.WNL.0000055899.24594.8E","article-title":"Effects of Dopa on plasma homocysteine in PD patients Relationship to vitamin status","volume":"60","author":"Miller","year":"2003","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(03)00438-1","article-title":"Homocysteine and Alzheimer s disease","volume":"2","author":"Morris","year":"2003","journal-title":"Lancet Neurol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","article-title":"de Plasma homocysteine levels in Parkinson s disease : role of antiparkinsonian medications Parkinsonism","volume":"11","author":"Zoccolella","year":"2005","journal-title":"Relat Disord"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0404.2003.00135.x","article-title":"Levodopa - induced hyperhomocysteinemia in Parkinson s disease","volume":"108","author":"Yasui","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","article-title":"van Elevated plasma levels of homocysteine in Parkinson s disease","volume":"40","author":"Kuhn","year":"1998","journal-title":"Eur Neurol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","article-title":"de Effects of levo - dopa and COMT inhibitors on plasma homocysteine in PD patients","volume":"20","author":"Lamberti","year":"2005","journal-title":"Mov Dis"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1468-1331.2004.00973.x","article-title":"de Hyperhomocysteinemia in dopa treated Parkinson s disease patients : effect of cobalamin and folate administration","volume":"12","author":"Lamberti","year":"2005","journal-title":"Eur J Neurol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/mds.20253","article-title":"Modest increase in plasma homocysteine follows levodopa initiation in Parkinson s disease","volume":"19","author":"Suilleabhain","year":"2004","journal-title":"Mov Disord"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1161\/01.STR.0000032550.90046.38","article-title":"Moderately elevated plasma homocysteine , methylenetetrahydrofolate reductase genotype and risk for stroke , vascular dementia and Alzheimer disease in Northern Ireland","volume":"33","author":"McIlroy","year":"2002","journal-title":"Stroke"},{"key":"ref221","first-page":"677","article-title":"polymorphism folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson s disease","volume":"68","author":"Woitalla","year":"2004","journal-title":"J Neural Transm Suppl"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinchem\/47.6.1102","article-title":"Plasma homocysteine and dopa metabolism in patients with Parkinson s disease","volume":"47","author":"Blandini","year":"2001","journal-title":"Clin Chem"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","article-title":"Reduced plasma homocysteine levels in levodopa \/ entacapone treated Parkinson patients Parkinsonism","volume":"11","author":"Valkovic","year":"2005","journal-title":"Relat Disord"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini - Mental State : a practical method for grading the cognitive state for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatry Res"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1474-4422(03)00351-X","article-title":"Dementia associated with Parkinson s disease","volume":"2","author":"Emre","year":"2003","journal-title":"Lancet Neurol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","article-title":"Levodopa - associated increase of homocysteine levels and sural axonal neurodegeneration","volume":"61","author":"Muller","year":"2004","journal-title":"Arch Neurol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer s disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"Engl J Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1212\/01.WNL.0000055899.24594.8E","article-title":"Effect of dopa on plasma homocysteine in PD patients : relationship to vitamin status","volume":"60","author":"Miller","year":"2003","journal-title":"Neurology"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism : onset , progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","article-title":"Elevated plasma homocysteine levels in patients treated with levodopa Association with vascular disease","volume":"60","author":"Rogers","year":"2003","journal-title":"Arch Neurol"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2005.43.issue-10\/cclm.2005.193\/cclm.2005.193.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2005.193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T22:46:06Z","timestamp":1619045166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2005.193\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":31,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1515\/cclm.2005.193","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}